CoChat
Sign Up
Cited by 178

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives

dos Santos, Aline Martins, Carvalho, Suzana Gonçalves, Meneguin, Andréia Bagliotti, Sábio, Rafael Miguel, Gremião, Maria Palmira Daflon, Chorilli, Marlus·2021·Journal of Controlled Release
DOI 10.1016/j.jconrel.2021.04.026
Open this paper in CoChat — free account

Abstract

Colon-targeted oral delivery of drugs remains as an appealing and promising approach for the treatment of prevalent intestinal diseases (ID), such as inflammatory bowel disease (IBD) and colorectal cancer (CRC). Notwithstanding, there are numerous challenges to effective drug delivery to the colon, which requires the design of advanced strategies. Micro- and nanoparticles have received great attention as colon-targeted delivery platforms due to their reduced size and structural composition that favors the accumulation and/or residence time of drugs at the site of action and/or absorption, contributing to localized therapy. The choice by natural polysaccharides imparts key properties and advantages to the nano-in-microparticulate systems to effective colon-specific oral delivery. This review proposes to discuss the physiological barriers imposed by the gastrointestinal tract (GIT) against oral administration of drugs, as well as pathological factors and challenges of the ID for oral delivery of colon-targeted systems. We then provide an updated progress about polysaccharides-based colon-targeted drug delivery systems, including microparticulate, nanoparticulate and nano-in-microparticulate systems, highlighting their key properties, advantages and limitations to achieving targeted delivery and efficacious therapy within the colon. Lastly, we provide future perspectives, towards advances in the field and clinical translation of colon-targeted oral delivery systems for ID therap…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2021.04.026

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 79

  1. Zeeshan, 2019, Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease, Int. J. Pharm., 558, 201, 10.1016/j.ijpharm.2018.12.074 · DOI
  2. Hua, 2015, Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue, Nanomedicine, 11, 1117, 10.1016/j.nano.2015.02.018 · DOI · Paper page
  3. Kotla, 2019, Bioresponsive drug delivery systems in intestinal inflammation: state-of-the-art and future perspectives, Adv. Drug Deliv. Rev., 146, 248, 10.1016/j.addr.2018.06.021 · DOI
  4. Arévalo-Pérez, 2020, Recent advances in colon drug delivery systems, J. Control. Release, 327, 703, 10.1016/j.jconrel.2020.09.026 · DOI · Paper page
  5. Xu, 2019, Reversing tumor stemness via orally targeted nanoparticles achieves efficient colon cancer treatment, Biomaterials., 216, 119247, 10.1016/j.biomaterials.2019.119247 · DOI
  6. Amidon, 2015, Colon-targeted oral drug delivery systems: design trends and approaches, AAPS PharmSciTech, 16, 731, 10.1208/s12249-015-0350-9 · DOI · Paper page
  7. Collnot, 2012, Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa, J. Control. Release, 161, 235, 10.1016/j.jconrel.2012.01.028 · DOI
  8. Zhang, 2016, Polysaccharide-based micro/nanocarriers for oral colon-targeted drug delivery, J. Drug Target., 24, 579, 10.3109/1061186X.2015.1128941 · DOI
  9. Khare, 2020, Natural product-based nanomedicine in treatment of inflammatory bowel disease, Int. J. Mol. Sci., 21, 10.3390/ijms21113956 · DOI
  10. Agüero, 2017, Alginate microparticles as oral colon drug delivery device: a review, Carbohydr. Polym., 168, 32, 10.1016/j.carbpol.2017.03.033 · DOI
  11. Prabaharan, 2011, Prospective of guar gum and its derivatives as controlled drug delivery systems, Int. J. Biol. Macromol., 49, 117, 10.1016/j.ijbiomac.2011.04.022 · DOI
  12. Tripodo, 2015, Hyaluronic acid and its derivatives in drug delivery and imaging: recent advances and challenges, Eur. J. Pharm. Biopharm., 97, 400, 10.1016/j.ejpb.2015.03.032 · DOI
  13. Xiao, 2017, Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis, Mol. Ther., 25, 1628, 10.1016/j.ymthe.2016.11.020 · DOI
  14. Liu, 2003, Pectin-based systems for colon-specific drug delivery via oral route, Biomaterials., 24, 3333, 10.1016/S0142-9612(03)00213-8 · DOI
  15. Htoon, 2010, The effect of acid dextrinisation on enzyme-resistant starch content in extruded maize starch, Food Chem., 120, 140, 10.1016/j.foodchem.2009.09.094 · DOI
  16. Bagliotti Meneguin, 2014, Films from resistant starch-pectin dispersions intended for colonic drug delivery, Carbohydr. Polym., 99, 140, 10.1016/j.carbpol.2013.07.077 · DOI
  17. Abu-Huwaij, 2011, Formulation and in vitro evaluation of xanthan gum or carbopol 934-based mucoadhesive patches, loaded with nicotine, AAPS PharmSciTech, 12, 21, 10.1208/s12249-010-9534-5 · DOI
  18. Singh, 2015, Ananomedicine-promising approach to provide an appropriate colon-targeted drug delivery system for 5-fluorouracil, Int. J. Nanomedicine, 10, 7175
  19. Zhang, 2018, Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis, Inflamm. Bowel Dis., 24, 1401, 10.1093/ibd/izy123 · DOI
  20. Schiller, 2005, Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging, Aliment. Pharmacol. Ther., 22, 971, 10.1111/j.1365-2036.2005.02683.x · DOI
  21. McConnell, 2008, Gut instincts: explorations in intestinal physiology and drug delivery, Int. J. Pharm., 364, 213, 10.1016/j.ijpharm.2008.05.012 · DOI
  22. Ensign, 2012, Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers, Adv. Drug Deliv. Rev., 64, 557, 10.1016/j.addr.2011.12.009 · DOI
  23. Lautenschläger, 2014, Drug delivery strategies in the therapy of inflammatory bowel disease, Adv. Drug Deliv. Rev., 71, 58, 10.1016/j.addr.2013.10.001 · DOI
  24. Baumgart, 2005, Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism, Scand. J. Gastroenterol., 40, 958, 10.1080/00365520510015854 · DOI
  25. Danese, 2015, Biologic agents for IBD: practical insights, Nat. Rev. Gastroenterol. Hepatol., 12, 537, 10.1038/nrgastro.2015.135 · DOI
  26. Zhou, 1999, Intestinal metabolism and transport of 5-aminosalicylate, Drug Metab. Dispos., 27, 10.1016/S0090-9556(24)15210-5 · DOI
  27. Nunthanid, 2008, Development of time-, pH-, and enzyme-controlled colonic drug delivery using spray-dried chitosan acetate and hydroxypropyl methylcellulose, Eur. J. Pharm. Biopharm., 68, 253, 10.1016/j.ejpb.2007.05.017 · DOI
  28. Shahdadi Sardo, 2019, A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems, Int. J. Pharm., 558, 367, 10.1016/j.ijpharm.2019.01.022 · DOI · Paper page
  29. Ye, 2015, Mesalazine preparations for the treatment of ulcerative colitis: are all created equal?, World J. Gastrointest. Pharmacol. Ther., 6, 137, 10.4292/wjgpt.v6.i4.137 · DOI
  30. Goyanes, 2015, Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations, Int. J. Pharm., 484, 103, 10.1016/j.ijpharm.2015.02.051 · DOI
  31. Klotz, 2005, Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease, Adv. Drug Deliv. Rev., 57, 267, 10.1016/j.addr.2004.08.007 · DOI
  32. Carrette, 1995, Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn’s disease, Dig. Dis. Sci., 40, 2641, 10.1007/BF02220454 · DOI
  33. Carlson, 1999, Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion, Am. J. Gastroenterol., 94, 1876, 10.1111/j.1572-0241.1999.01223.x · DOI
  34. HARDY, 1985, Drug delivery to the proximal colon, J. Pharm. Pharmacol., 37, 874, 10.1111/j.2042-7158.1985.tb04992.x · DOI
  35. Keum, 2019, Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies, Nat. Rev. Gastroenterol. Hepatol., 16, 713, 10.1038/s41575-019-0189-8 · DOI
  36. Matos, 2019, Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer, J. Control. Release, 307, 108, 10.1016/j.jconrel.2019.06.017 · DOI
  37. Luis de Redín, 2020, In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer, Drug Deliv. Transl. Res., 10, 635, 10.1007/s13346-020-00722-7 · DOI
  38. Wan, 2020, Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy, J. Control. Release, 322, 236, 10.1016/j.jconrel.2020.03.015 · DOI
  39. You, 2016, Polymeric nanoparticles for colon cancer therapy: overview and perspectives, J. Mater. Chem. B, 4, 7779, 10.1039/C6TB01925K · DOI
  40. Akhter, 2020, Oral delivery of multicompartment nanomedicines for colorectal cancer therapeutics: combining loco-regional delivery with cell-target specificity, Adv. Ther., 3, 1900171, 10.1002/adtp.201900171 · DOI
  41. Kato, 2013, Acidic extracellular microenvironment and cancer, Cancer Cell Int., 13, 1, 10.1186/1475-2867-13-89 · DOI
  42. Suarato, 2016, Role of p H-responsiveness in the design of chitosan-based cancer nanotherapeutics: A review, Biointerphases, 11, 10.1116/1.4944661 · DOI
  43. Maiti, 2011, Al +3 ion cross-linked and acetalated gellan hydrogel network beads for prolonged release of glipizide, Carbohydr. Polym., 85, 164, 10.1016/j.carbpol.2011.02.010 · DOI
  44. Nidhi, 2016, Mishra, microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: a brief review, Saudi pharm, J., 24, 458
  45. Lamprecht, 2001, Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa, Pharm. Res., 18, 788, 10.1023/A:1011032328064 · DOI · Paper page
  46. Cao, 2019, Alginate/chitosan microcapsules for in-situ delivery of the protein, interleukin-1 receptor antagonist (IL-1Ra), for the treatment of dextran sulfate sodium (DSS)-induced colitis in a mouse model, Eur. J. Pharm. Biopharm., 137, 112, 10.1016/j.ejpb.2019.02.011 · DOI
  47. Clemett, 2000, Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn’s disease, Drugs., 59, 929, 10.2165/00003495-200059040-00016 · DOI
  48. Mladenovska, 2007, Colon-specific delivery of 5-aminosalicylic acid from chitosan-ca-alginate microparticles, Int. J. Pharm., 342, 124, 10.1016/j.ijpharm.2007.05.028 · DOI
  49. Wang, 2016, Colon targeted oral drug delivery system based on alginate-chitosan microspheres loaded with icariin in the treatment of ulcerative colitis, Int. J. Pharm., 515, 176, 10.1016/j.ijpharm.2016.10.002 · DOI
  50. Helmy, 2020, High-payload chitosan microparticles for the colonic delivery of quercetin: development and in-vivo evaluation in a rabbit colitis model, J. Drug Deliv. Sci. Technol., 58, 101832, 10.1016/j.jddst.2020.101832 · DOI
  51. Mura, 2011, N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: in vivo study with TNBS-induced colitis model in rats, Int. J. Pharm., 416, 145
  52. Deng, 2019, Colon-specific microspheres loaded with puerarin reduce tumorigenesis and metastasis in colitis-associated colorectal cancer, Int. J. Pharm., 570, 118644, 10.1016/j.ijpharm.2019.118644 · DOI
  53. Kang, 2020, Guar gum micro-particles for targeted co-delivery of doxorubicin and Metformin HCL for improved specificity and efficacy against colon cancer: in vitro and in vivo studies, AAPS PharmSciTech, 21, 10.1208/s12249-019-1589-3 · DOI
  54. Ahmad, 2013, Colorectal cancer targeted irinotecan-Assam bora rice starch based microspheres: a mechanistic, pharmacokinetic and biochemical investigation, Drug Dev. Ind. Pharm., 39, 1936, 10.3109/03639045.2012.719906 · DOI
  55. Karan, 2019, Polymeric microsphere formulation for colon targeted delivery of 5-fluorouracil using biocompatible natural gum katira, Asian Pac. J. Cancer Prev., 20, 2181, 10.31557/APJCP.2019.20.7.2181 · DOI
  56. Karan, 2020, In-vitro and in-vivo evaluation of polymeric microsphere formulation for colon targeted delivery of 5-fluorouracil using biocompatible natural gum katira, Int. J. Biol. Macromol., 158, 922, 10.1016/j.ijbiomac.2020.04.129 · DOI
  57. Nel, 2009, Understanding biophysicochemical interactions at the nano-bio interface, Nat. Mater., 8, 543, 10.1038/nmat2442 · DOI · Paper page
  58. Banerjee, 2016, Role of nanoparticle size, shape and surface chemistry in oral drug delivery, J. Control. Release, 238, 176, 10.1016/j.jconrel.2016.07.051 · DOI
  59. Lee, 2019, Soluble eggshell membrane protein-loaded chitosan/fucoidan nanoparticles for treatment of defective intestinal epithelial cells, Int. J. Biol. Macromol., 131, 949, 10.1016/j.ijbiomac.2019.03.113 · DOI
  60. Yi, 2004, Soluble eggshell membrane protein: preparation, characterization and biocompatibility, Biomaterials., 25, 4591, 10.1016/j.biomaterials.2003.11.052 · DOI
  61. Benson, 2012, Effects of natural eggshell membrane (NEM) on cytokine production in cultures of peripheral blood mononuclear cells: increased suppression of tumor necrosis factor- α levels after in vitro digestion, J. Med. Food, 15, 360, 10.1089/jmf.2011.0197 · DOI
  62. Fonseca-Santos, 2016, Design, characterization, and biological evaluation of curcumin-loaded surfactant-based systems for topical drug delivery, Int. J. Nanomedicine, 11, 4553, 10.2147/IJN.S108675 · DOI
  63. Carolina Alves, 2019, A critical review of the properties and analytical methods for the determination of curcumin in biological and pharmaceutical matrices, Crit. Rev. Anal. Chem., 49, 138, 10.1080/10408347.2018.1489216 · DOI
  64. Oshi, 2020, Curcumin nanocrystal/pH-responsive polyelectrolyte multilayer core–shell nanoparticles for inflammation-targeted alleviation of ulcerative colitis, Biomacromolecules., 21, 3571, 10.1021/acs.biomac.0c00589 · DOI
  65. Wang, 2019, Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3- gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles, Nanomedicine, 21, 102068, 10.1016/j.nano.2019.102068 · DOI
  66. Ferreira, 2020, Design of chitosan-based particle systems: A review of the physicochemical foundations for tailored properties, Carbohydr. Polym., 250, 10.1016/j.carbpol.2020.116968 · DOI
  67. Chuah, 2014, Cellular uptake and anticancer effects of mucoadhesive curcumin-containing chitosan nanoparticles, Colloids Surf. B: Biointerfaces, 116, 228, 10.1016/j.colsurfb.2014.01.007 · DOI
  68. Sabra, 2019, Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer, Int. J. Pharm., 572, 118775, 10.1016/j.ijpharm.2019.118775 · DOI
  69. Alkhader, 2018, Pharmacokinetic and anti-colon cancer properties of curcumin-containing chitosan-pectinate composite nanoparticles, J. Biomater. Sci. Polym. Ed., 29, 2281, 10.1080/09205063.2018.1541500 · DOI · Paper page
  70. Boni, 2018, Mucoadhesive nanostructured polyelectrolytes complexes modulate the intestinal permeability of methotrexate, Eur. J. Pharm. Sci., 111, 73, 10.1016/j.ejps.2017.09.042 · DOI
  71. Badran, 2017, Preparation and characterization of polymeric nanoparticles surface modified with chitosan for target treatment of colorectal cancer, Int. J. Biol. Macromol., 95, 643, 10.1016/j.ijbiomac.2016.11.098 · DOI · Paper page
  72. Musa, 2020, Design of polysaccharidic nano-in-micro soft agglomerates as primary oral drug delivery vehicle for colon-specific targeting, Carbohydr. Polym., 247, 10.1016/j.carbpol.2020.116673 · DOI
  73. Ma, 2015, The in vivo fate of nanoparticles and nanoparticle-loaded microcapsules after oral administration in mice: evaluation of their potential for colon-specific delivery, Eur. J. Pharm. Biopharm., 94, 393, 10.1016/j.ejpb.2015.06.014 · DOI
  74. Glavas Dodov, 2009, Wheat germ agglutinin-conjugated chitosan-ca-alginate microparticles for local colon delivery of 5-FU: development and in vitro characterization, Int. J. Pharm., 381, 166, 10.1016/j.ijpharm.2009.06.037 · DOI
  75. Imperiale, 2013, Nanoparticle-in-Microparticle Delivery Systems (NiMDS): Production, Administration Routes and Clinical Potential, J. Biomater. Tissue Eng., 3, 22, 10.1166/jbt.2013.1064 · DOI
  76. Glavas-Dodov, 2013, Wheat germ agglutinin-functionalised crosslinked polyelectrolyte microparticles for local colon delivery of 5-FU: in vitro efficacy and in vivo gastrointestinal distribution, J. Microencapsul., 30, 643, 10.3109/02652048.2013.770099 · DOI
  77. Garrait, 2014, Development of a novel drug delivery system: chitosan nanoparticles entrapped in alginate microparticles, J. Microencapsul., 31, 363, 10.3109/02652048.2013.858792 · DOI
  78. dos Santos, 2021, Understanding the role of colon-specific microparticles based on retrograded starch/pectin in the delivery of chitosan nanoparticles along the gastrointestinal tract, Eur. J. Pharm. Biopharm., 158, 371, 10.1016/j.ejpb.2020.12.004 · DOI
  79. Ling, 2019, Alginate/chitosan microparticles for gastric passage and intestinal release of therapeutic protein nanoparticles, J. Control. Release, 295, 174, 10.1016/j.jconrel.2018.12.017 · DOI

Cited by

Sorted by citations

Metadata

Authors
dos Santos, A. M., Carvalho, S. G., Meneguin, A. B., Sábio, R. M., Gremião, M. P. D., & Chorilli, M.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2021-06
Volume
334
Pages
353-366
ISSN
0168-3659
DOI
10.1016/j.jconrel.2021.04.026
Cited by
178
References
3
Language
en
Licence
Funders
  • State of Sao Paulo Research Foundation
  • National Council for Scientific and Technological Development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review